Shares of Hims & Hers were on fire Monday because the FDA's new leader seems to be a fan of the company's business model.

Hims & Hers achieved a 44% YoY increase in Q3 2024, surpassing 2 million active users. Find out what positions HIMS as a key ...

Hims & Hers offers personalized telehealth services, with a stock price that reflects high-growth potential. See why we ...

Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions ...

Hims & Hers Health Inc. shares surged 24% to close at fresh record after Hunterbrook Media said the company is poised to be a ...

Shares of Hims & Hers Health slumped 15% on Thursday after Amazon.com launched a rival service that offers upfront pricing ...

Shares of Hims & Hers are moving higher after President-elect Donald Trump nominated Dr. Marty Makary, a pancreatic surgeon at Johns ...

The millennial-skewed telehealth platform Hims & Hers (HIMS) announced Monday that it will start offering customers a generic ...

Shares of Hims & Hers Health jumped after the company added former Food and Drug Administration official Deb Autor to its board. The stock was up 8.8% at $21.02 in Monday trading. Shares have doubled ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Hims & Hers Health (HIMS – Research Report) and Celcuity (CELC – Research Report). Don't Miss our Black ...

Hims & Hers Health, Inc. (“Hims & Hers”) (NYSE: HIMS), the leading health and wellness platform, today announced Deb Autor, ...